IL4 and Alzheimer disease: Dupilumab, a monoclonal antibody that blocks interleukin-4 and interleukin-13 signaling, works by blocking specific immune pathways involved in the pathogenesis of AD (4), and has demonstrated significant efficacy in improving patients’ symptoms, attenuating inflammatory responses, and increasing remission rates (5, 6), which represents a therapeutic breakthrough for moderate-to-severe AD.